Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
D000612:4-Aminobutyrate Transaminase / Q000378:metabolism; D000344:Afferent Pathways / Q000502:physiology; D000614:Aminocaproates / Q000494:pharmacology; D000818:Animals; D001479:Basal Ganglia / Q000502:physiology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D003342:Corpus Striatum / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D004525:Efferent Pathways / Q000502:physiology; D018756:GABA Antagonists; D005969:Glutamate Dehydrogenase / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000503:physiopathology; D009118:Muscimol / Q000494:pharmacology; D009474:Neurons / Q000502:physiology; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D011954:Receptors, Dopamine / Q000502:physiology; D011963:Receptors, GABA-A; D012559:Schizophrenia / Q000188:drug therapy; D012701:Serotonin / Q000378:metabolism; D013378:Substantia Nigra / Q000502:physiology*; D013569:Synapses / Q000502:physiology; D009435:Synaptic Transmission; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D000614:Aminocaproates; D018492:Dopamine Antagonists; D018756:GABA Antagonists; D011956:Receptors, Cell Surface; D011954:Receptors, Dopamine; D011963:Receptors, GABA-A; D009118:Muscimol; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D014446:Tyrosine 3-Monooxygenase; D005969:Glutamate Dehydrogenase; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin; D002746:Chlorpromazine; D004298:Dopamine